The American Society of Clinical Oncology on Friday released guidelines to help guide use of multigene germline genetic testing panels for cancer patients.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU.

Analysis of molecules that travel from the brain into the blood could enable noninvasive monitoring of gene expression in the organ, according to research published in Nature Biotechnology.

The US Food and Drug Administration announced on Tuesday that it has approved AutoGenomics' test to determine whether a patient has an elevated risk of developing opioid use disorder (OUD).

Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted therapies.

An expert panel led by researchers at the Ohio State University Wrexner Medical Center and College of Medicine has published a set of evidence-based guidelines for genetic testing and counseling for people with amyotrophic lateral sclerosis (ALS).

By studying cell-free DNA methylation (cfDNAme) patterns among pregnant women, researchers in Belgium have developed a liquid biopsy screening test to identify women at risk of early-onset preeclampsia (PE).

QIAGEN announced today the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry.